Nouscom

Private

#Cancer Vaccines #Immuno-Oncology #Lynch Syndrome #Colorectal Cancer #Neoantigen Therapy

Nouscom is a clinical-stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines on a proprietary viral-vector platform, including the NOUS-209 program in Lynch syndrome and neoantigen vaccines encoding hundreds of tumor-specific antigens. It operates from Basel, Switzerland and Rome, Italy.

Company Info

Sector:Biotechnology / Immuno-Oncology

Headquarters:Rome, Italy

Founded:2015

Website:nouscom.com/

Funding Round:Series D

Clinical Development Pipeline

NOUS-209

Target: Off-the-shelf viral-vectored cancer vaccine (209 shared neoantigens)

Lynch syndrome / MSI-high solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

NOUS-PEV

Target: Personalized neoantigen vaccine (prime-boost viral vectors)

Advanced melanoma and solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Marina Udier, PhD

Chief Executive Officer

Tiffany Muller

Chief Financial Officer

Sven Gogov, MD

Chief Medical Officer

Careers & Job Openings

See all open roles

Careers

Basel, Switzerland / Rome, Italy

Apply Now →